The biotechnology and pharmaceutical (biopharma) industry expects a fifth of its annual revenue to come from connected health services/products in the next five years, according to a new Capgemini report.

The connected healthcare market is growing exponentially. The Covid-19 pandemic, and being prevented from seeing healthcare providers (HCPs) face-to-face, spurred on the integration of digital technology into healthcare.

From mobile apps and smart medication adherence monitors to the integration of generative AI technologies, the adoption of connected health continues to accelerate post-pandemic.

According to Market.US, a market research and analysis company, the global connected health market is projected to grow at a compound annual growth rate of 25%, reaching $520.6bn by 2032 from $58.2bn in 2022.

The drivers for integrating these digital technologies into healthcare, many of which are data-driven and AI-powered, are improving clinical insights and patient outcomes.

A new report from...